Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 4, 2019

Deals this week: Antengene Corporation, Acer Therapeutics, Menarini

Antengene Corporation has raised $120m in a series B funding round led by Boyu Capital and FountainVest.

Antengene Corporation has raised $120m in a series B funding round led by Boyu Capital and FountainVest.

The funding round also included participation from new investors Celgene Corporation, WuXi Corporate Venture Fund, and Taikang, along with previous investors Qiming Venture Partners and TF Capital.

Proceeds will go towards the development of Antengene’s lead candidate ATG-008 and ATG-010 (selinexor). Funds will also be used for research and development (R&D) activities and partnerships and the commercial launch of late-stage candidates.

Antengene is a clinical-stage biopharmaceutical company based in China.

Acer Therapeutics will acquire global rights to Sanofi’s investigational drug candidate osanetant after entering a partnership.

Osanetant is a tachykinin NK3 receptor antagonist.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Acer intends to develop the drug as a potential treatment for various neuroendocrine disorders.

Acer Therapeutics and Sanofi are pharmaceutical companies based in the US and France respectively.

Menarini Group’s German subsidiary Berlin Chemie has acquired the worldwide commercialisation rights to Helsinn Group’s clinical-stage drug candidate pracinostat.

“Menarini Group’s German subsidiary Berlin Chemie has acquired the worldwide commercialisation rights to Helsinn Group’s clinical-stage drug candidate pracinostat.”

Menarini will be responsible for the promotion, distribution and marketing of the drug in all regions excluding the US, Canada, Japan and South America, while Helsinn will have the international development and supply rights to the drug.

Helsinn will also hold the right to co-promote pracinostat along with Menarini in the Shanghai province of China.

Menarini is a biopharmaceutical company based in Italy, while Helsinn is a Swiss pharmaceutical company.

Helix BioPharma has completed the final tranche of private placement of units priced at $1.20 each to raise C$348,000 ($255,578).

Each unit includes one common share and one common share purchase warrant, which grants the holder to buy an additional common share at $1.5 within five years of the date of issuance.

Canada-based biopharmaceutical company Helix Biopharma plans to utilise the proceeds towards working capital requirements and R&D expenditure.

InventisBio will co-develop Betta Pharma’s cancer drug candidate D-0316 after the two companies collaborated.

D-0316 is being developed as a potential treatment for EGFR-mutant non-small cell lung cancer.

The agreement will see Betta hold the commercialisation rights to the drug candidate in China.

InventisBio will receive an upfront amount and R&D milestones payments worth RMB230m ($33.4m) from Betta Pharma.

It is also eligible to receive several other milestones and royalties based on the annual sales of the drug after successful commercialisation.

Both based in China, InventisBio is a biotechnology company, while Betta Pharma is a pharmaceutical company.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU